Swedish Orphan Biovitrum ... (BIOVF)
Swedish Orphan Biovitrum AB (publ) Statistics
Share Statistics
Swedish Orphan Biovitrum AB (publ) has 343.44M shares outstanding. The number of shares has increased by 1.05% in one year.
| Shares Outstanding | 343.44M |
| Shares Change (YoY) | 1.05% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 178.11M |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is 26.92 and the forward PE ratio is null. Swedish Orphan Biovitrum AB (publ)'s PEG ratio is 0.5.
| PE Ratio | 26.92 |
| Forward PE | n/a |
| PS Ratio | 4.02 |
| Forward PS | n/a |
| PB Ratio | 2.6 |
| P/FCF Ratio | 23.86 |
| PEG Ratio | 0.5 |
Enterprise Valuation
Swedish Orphan Biovitrum AB (publ) has an Enterprise Value (EV) of 120.16B.
| EV / Sales | 4.62 |
| EV / EBITDA | 12.91 |
| EV / EBIT | 16.26 |
| EV / FCF | 27.42 |
Financial Position
The company has a current ratio of 1.04, with a Debt / Equity ratio of 0.42.
| Current Ratio | 1.04 |
| Quick Ratio | 0.71 |
| Debt / Equity | 0.42 |
| Debt / EBITDA | 1.8 |
| Debt / FCF | 3.82 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is 9.64% and Return on Invested Capital is 7.4%.
| Return on Equity | 9.64% |
| Return on Assets | 5.15% |
| Return on Invested Capital | 7.4% |
| Revenue Per Employee | $13.73M |
| Profits Per Employee | $2.05M |
| Employee Count | 1,895 |
| Asset Turnover | 0.34 |
| Inventory Turnover | 1.39 |
Taxes
| Income Tax | 528M |
| Effective Tax Rate | 11.98% |
Stock Price Statistics
The stock price has increased by 26.8% in the last 52 weeks. The beta is 0.3, so Swedish Orphan Biovitrum AB (publ)'s price volatility has been higher than the market average.
| Beta | 0.3 |
| 52-Week Price Change | 26.8% |
| 50-Day Moving Average | 28.82 |
| 200-Day Moving Average | 28.77 |
| Relative Strength Index (RSI) | 75.28 |
| Average Volume (20 Days) | 86 |
Income Statement
In the last 12 months, Swedish Orphan Biovitrum AB (publ) had revenue of 26.03B and earned 3.88B in profits. Earnings per share was 11.37.
| Revenue | 26.03B |
| Gross Profit | 20.24B |
| Operating Income | 5.63B |
| Net Income | 3.88B |
| EBITDA | 9.3B |
| EBIT | 5.63B |
| Earnings Per Share (EPS) | 11.37 |
Balance Sheet
The company has 1.14B in cash and 16.73B in debt, giving a net cash position of -15.6B.
| Cash & Cash Equivalents | 1.14B |
| Total Debt | 16.73B |
| Net Cash | -15.6B |
| Retained Earnings | 21.92B |
| Total Assets | 75.44B |
| Working Capital | 562M |
Cash Flow
In the last 12 months, operating cash flow was 7.39B and capital expenditures -3B, giving a free cash flow of 4.38B.
| Operating Cash Flow | 7.39B |
| Capital Expenditures | -3B |
| Free Cash Flow | 4.38B |
| FCF Per Share | 12.83 |
Margins
Gross margin is 77.77%, with operating and profit margins of 21.61% and 14.93%.
| Gross Margin | 77.77% |
| Operating Margin | 21.61% |
| Pretax Margin | 16.93% |
| Profit Margin | 14.93% |
| EBITDA Margin | 35.75% |
| EBIT Margin | 21.61% |
| FCF Margin | 16.84% |
Dividends & Yields
BIOVF does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 3.72% |
| FCF Yield | 4.19% |
Analyst Forecast
Currently there are no analyst rating for BIOVF.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Aug 28, 2023. It was a forward split with a ratio of 523:500.
| Last Split Date | Aug 28, 2023 |
| Split Type | forward |
| Split Ratio | 523:500 |
Scores
| Altman Z-Score | 1.18 |
| Piotroski F-Score | 7 |